The Green lab is investigating new immunotherapy based approaches to treat multiple myeloma (MM) and lymphoma. Ideally, a tumor target (antigen) should be expressed homogeneously on the cancer cell’s surface and not be found on normal tissue. Dr. Green and his team have been studying the CD38 antigen for the past decade and have successfully developed CD38 pretargeted radioimmunotherapy (PRIT) effectively eliminating >90% of myeloma tumors in preclinical models. He is currently exploring measures to further enhance the efficacy of this approach, both through the use of alpha emitting radionuclides and bispecific antibodies (in both myeloma and lymphoma).
Dr. Green is also actively developing other forms of immunotherapy to treat multiple myeloma with a major focus on the development of chimeric antigen receptor (CAR)-T cell therapy. As a translational researcher, Dr. Green is using the unique and unparalleled resources at the Fred Hutch to bring his research discoveries to patients rapidly in the form of clinical trials. Dr. Green is the principal investigator on multiple federal and foundation supported grants, is invited nationally and internationally to present his research findings and speaks to both physicians and patients around the nation on advances in multiple myeloma research.
Dr. Green's mentor, Oliver W. Press, MD PhD, passed away September 29, 2017. Memorial gifts may be made to the Oliver “Ollie” W. Press Award for Extraordinary Mentorship.